Neurocrine Biosciences Inc (NBIX) insider trading
Every open-market stock purchase and sale by Neurocrine Biosciences Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Matt Abernethy (CFO) and 3 others sold $1.1M in the last 90 days.
- Last insider buy: Bvf Partners L P/il (10% owner), $133K, 15 years ago.
Last 12 months: insiders bought $0 (0 buys) and sold $77.9M (26 sales). Last close $141.31 on Oct 21, 2026.
Recent NBIX insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Sep 14, 2026 | Matt Abernethy (CFO) | Sold | $363K |
| Sep 14, 2026 | David W. Boyer (Officer) | Sold | $130K |
| Sep 11, 2026 | Kevin Charles Gorman (Director) | Sold (not open market) | $1.2M |
| Sep 11, 2026 | Eric Benevich (C-suite exec) | Sold (not open market) | $529K |
| Sep 11, 2026 | Kyle Gano (CEO) | Sold (not open market) | $529K |
| Sep 11, 2026 | Matt Abernethy (CFO) | Sold (not open market) | $423K |
| Sep 11, 2026 | Ingrid Delaet (C-suite exec) | Sold (not open market) | $378K |
| Sep 11, 2026 | Darin Lippoldt (C-suite exec) | Sold (not open market) | $378K |
| Sep 11, 2026 | Sanjay Chandru Keswani (C-suite exec) | Sold (not open market) | $330K |
| Sep 11, 2026 | David W. Boyer (Officer) | Sold (not open market) | $302K |
| Sep 11, 2026 | Julie Cooke (Officer) | Sold (not open market) | $302K |
| Sep 11, 2026 | Jude Onyia (C-suite exec) | Sold (not open market) | $302K |
| Sep 11, 2026 | Kyle Gano (CEO) | Sold (not open market) | $155K |
| Sep 11, 2026 | Kyle Gano (CEO) | Bought (not open market) | — |
| Sep 11, 2026 | Eric Benevich (C-suite exec) | Bought (not open market) | — |
| Sep 11, 2026 | Kyle Gano (CEO) | Bought (not open market) | — |
| Sep 11, 2026 | Julie Cooke (Officer) | Bought (not open market) | — |
| Sep 11, 2026 | Darin Lippoldt (C-suite exec) | Bought (not open market) | — |
| Sep 11, 2026 | Sanjay Chandru Keswani (C-suite exec) | Bought (not open market) | — |
| Sep 11, 2026 | Kevin Charles Gorman (Director) | Bought (not open market) | — |
| Sep 11, 2026 | Jude Onyia (C-suite exec) | Bought (not open market) | — |
| Sep 11, 2026 | Ingrid Delaet (C-suite exec) | Bought (not open market) | — |
| Sep 11, 2026 | Matt Abernethy (CFO) | Bought (not open market) | — |
| Sep 11, 2026 | David W. Boyer (Officer) | Bought (not open market) | — |
| Sep 9, 2026 | Eric Benevich (C-suite exec) | Sold | $333K |
Who's trading NBIX
- Matt Abernethy, CFO: sold $363K (1 sale), last Sep 14, 2026
- David W. Boyer, Officer: sold $739K (2 sales), last Sep 14, 2026
- Ingrid Delaet, C-suite exec: sold $3.7M (5 sales), last Sep 11, 2026
- Kevin Charles Gorman, Director: sold $37.8M (1 sale), last Sep 11, 2026
- Kyle Gano, CEO: sold $4.9M (3 sales), last Sep 11, 2026
- Sanjay Chandru Keswani, C-suite exec: other filings, last Sep 11, 2026
- Eric Benevich, C-suite exec: sold $1.2M (2 sales), last Sep 11, 2026
- Darin Lippoldt, C-suite exec: sold $4.2M (5 sales), last Sep 11, 2026
- Julie Cooke, Officer: sold $5.8M (5 sales), last Sep 11, 2026
- Jude Onyia, C-suite exec: sold $3.5M (2 sales), last Sep 11, 2026
- Stephen A Sherwin, Director: sold $4.1M (5 sales), last Sep 2, 2026
- Leslie V Norwalk, Director: sold $2M (5 sales), last Jul 29, 2026
- Shalini Sharp, Director: other filings, last May 27, 2026
- Gary A Lyons, Director: sold $2.3M (1 sale), last May 27, 2026
- George J Morrow, Director: sold $2.2M (1 sale), last May 27, 2026
Get free alerts when an insider at Neurocrine Biosciences Inc files a new trade →